Immuno-Biological Laboratories Co.,Ltd.

4570

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-07FY2027 Q1

Revenue

10.8100M JPY

YoY +13.5%

Operating Income

1.2100M JPY

YoY +116.5%

Net Income

3.7100M JPY

YoY +42.4%

EPS

10.8JPY

YoY +64.5%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

10億円

6.8億円

3.6億円

33.9百万円

-2.9億円

Rev: 6.5億円Op: -1.2億円NI: -2.6億円

Rev: 7.9億円Op: 58.4百万円NI: -2.9億円

Rev: 8.2億円Op: 1億円NI: 1.9億円

Rev: 9.7億円Op: 2.1億円NI: 2.5億円

Rev: 10億円Op: 2.8億円NI: 3.3億円

2022/FY2023/FY2024/FY2025/FY2026/FY

Full-Year Progress

FY2027 Q1

Net Income28.8%

Revenue Progress2.900M

Revenue Forecast10.900M

Net Income Progress100M

Net Income Forecast3.500M

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan